Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BHVN Stock Summary
Top 10 Correlated ETFs
BHVN
In the News
How Biohaven's experimental obesity drug could prevent muscle loss
Vlad Coric, Biohaven CEO, joins 'Fast Money' to discuss the weight loss drug wars and the company's experimental obesity drug.
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW HAVEN, Conn. , Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd.
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice.
Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?
Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going
Biohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.
Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug
Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.
Why Biohaven Stock Is Skyrocketing Today
Biohaven released a new investor presentation that featured encouraging information about drug candidate BHV-1300. The experimental drug showed promise in treating autoimmune diseases.
BHVN Financial details
BHVN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 12.91 | 0 | 0 | |
Net income per share | -10.91 | -3.31 | -5.97 | -12.75 | -5.73 | |
Operating cash flow per share | -7.78 | -2.12 | -4.07 | -6.65 | -4.66 | |
Free cash flow per share | -7.83 | -2.2 | -4.1 | -7.57 | -4.7 | |
Cash per share | 6.53 | 8.53 | 7.5 | 10.4 | 5.38 | |
Book value per share | -0.15 | 0.47 | 0.97 | 12.04 | 6.01 | |
Tangible book value per share | -0.15 | 1.05 | 2.09 | 11.6 | 5.73 | |
Share holders equity per share | -0.15 | 0.47 | 0.97 | 12.04 | 6.01 | |
Interest debt per share | -0.26 | 7.49 | 16.35 | 1.51 | 0.43 | |
Market cap | 2.64B | 3.07B | 4.94B | 621.01M | 3.05B | |
Enterprise value | 2.32B | 3.26B | 5.49B | 446.71M | 2.83B | |
P/E ratio | -4.99 | -25.87 | -23.09 | -1.09 | -7.47 | |
Price to sales ratio | 0 | 0 | 10.67 | 0 | 0 | |
POCF ratio | -7 | -40.42 | -33.85 | -2.09 | -9.19 | |
PFCF ratio | -6.95 | -39.04 | -33.63 | -1.83 | -9.1 | |
P/B Ratio | -355.58 | 182.97 | 142.3 | 1.15 | 7.12 | |
PTB ratio | -355.58 | 182.97 | 142.3 | 1.15 | 7.12 | |
EV to sales | 0 | 0 | 11.86 | 0 | 0 | |
Enterprise value over EBITDA | -4.85 | -28.45 | -25.23 | -0.79 | -6.54 | |
EV to operating cash flow | -6.16 | -42.86 | -37.63 | -1.5 | -8.53 | |
EV to free cash flow | -6.12 | -41.39 | -37.39 | -1.32 | -8.45 | |
Earnings yield | -0.2 | -0.04 | -0.04 | -0.92 | -0.13 | |
Free cash flow yield | -0.14 | -0.03 | -0.03 | -0.55 | -0.11 | |
Debt to equity | 0 | 15.98 | 18.08 | 0.13 | 0.07 | |
Debt to assets | 0 | 2.4 | 4.41 | 0.1 | 0.06 | |
Net debt to EBITDA | 0.66 | -1.62 | -2.53 | 0.31 | 0.51 | |
Current ratio | 4.96 | 3 | 2.26 | 6.52 | 7.98 | |
Interest coverage | 37.69 | 0 | 5.27 | 409.76 | 0 | |
Income quality | 0.71 | 0.64 | 0.68 | 0.52 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0.08 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0.39 | 0 | 0 | |
Intangibles to total assets | 0 | 0.35 | 0.14 | 0.03 | 0.04 | |
Capex to operating cash flow | 0.01 | 0.04 | 0.01 | 0.14 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -37.46 | -0.67 | -29.63 | -0.9 | |
Stock based compensation to revenue | 0 | 0 | 0.14 | 0 | 0 | |
Graham number | 6.13 | 5.91 | 11.4 | 58.77 | 27.84 | |
ROIC | 64.59 | -0.4 | -0.33 | -0.89 | -0.89 | |
Return on tangible assets | -1.54 | -1.64 | -1.75 | -0.89 | -0.83 | |
Graham Net | -0.72 | 10.63 | 6.48 | 9.05 | 4.33 | |
Working capital | 262.11M | 59.88M | 52.89M | 496.95M | 387.02M | |
Tangible asset value | -7.42M | 37.69M | 74.9M | 518.98M | 408.19M | |
Net current asset value | -23.41M | 55.04M | 47.45M | 463.96M | 357.21M | |
Invested capital | 0 | 15.98 | 18.08 | 0.13 | 0.07 | |
Average receivables | 0 | 60.06M | 65.01M | 28.03M | 29.89M | |
Average payables | 12.41M | 8.41M | 3.77M | 7.74M | 13.14M | |
Average inventory | 0 | 19.78M | 23.15M | 31.45M | 28.08M | |
Days sales outstanding | 0 | 0 | 7.82 | 0 | 0 | |
Days payables outstanding | 0 | 13.98K | 19.01 | 2.82K | 1.69K | |
Days of inventory on hand | 0 | 200.56K | 26.81 | 14.79K | 0 | |
Receivables turnover | 0 | 0 | 46.67 | 0 | 0 | |
Payables turnover | 0 | 0.03 | 19.2 | 0.13 | 0.22 | |
Inventory turnover | 0 | 0 | 13.61 | 0.02 | 0 | |
ROE | 71.23 | -7.07 | -6.16 | -1.06 | -0.95 | |
Capex per share | -0.05 | -0.08 | -0.03 | -0.92 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | -3.53 | 0 | 0 | 0 | 0 | |
Net income per share | -3.3 | -1.03 | -1.32 | -1.5 | -1.81 | |
Operating cash flow per share | -1.24 | -1.14 | -0.65 | -1.39 | -1.44 | |
Free cash flow per share | -1.24 | -1.15 | -0.66 | -1.41 | -1.44 | |
Cash per share | 7.65 | 5.69 | 4.91 | 3.52 | 4.79 | |
Book value per share | 8.85 | 6.92 | 5.67 | 4.24 | 5.35 | |
Tangible book value per share | 8.53 | 6.63 | 5.38 | 3.96 | 5.11 | |
Share holders equity per share | 8.85 | 6.92 | 5.67 | 4.24 | 5.35 | |
Interest debt per share | 1.12 | 0.32 | 0.43 | 0.46 | 0.39 | |
Market cap | 844.75M | 931.71M | 1.63B | 1.78B | 3.42B | |
Enterprise value | 670.46M | 836.43M | 1.51B | 1.7B | 3.2B | |
P/E ratio | -1.05 | -3.3 | -4.52 | -4.33 | -5.91 | |
Price to sales ratio | -3.93 | 0 | 0 | 0 | 0 | |
POCF ratio | -11.2 | -12 | -36.77 | -18.74 | -29.78 | |
PFCF ratio | -11.16 | -11.89 | -36.29 | -18.5 | -29.66 | |
P/B Ratio | 1.57 | 1.97 | 4.22 | 6.13 | 7.99 | |
PTB ratio | 1.57 | 1.97 | 4.22 | 6.13 | 7.99 | |
EV to sales | -3.12 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.15 | -10.99 | -16.42 | -15.35 | -20.96 | |
EV to operating cash flow | -8.89 | -10.77 | -34.1 | -17.9 | -27.87 | |
EV to free cash flow | -8.86 | -10.67 | -33.65 | -17.66 | -27.76 | |
Earnings yield | -0.24 | -0.08 | -0.06 | -0.06 | -0.04 | |
Free cash flow yield | -0.09 | -0.08 | -0.03 | -0.05 | -0.03 | |
Debt to equity | 0.13 | 0.06 | 0.08 | 0.11 | 0.07 | |
Debt to assets | 0.1 | 0.05 | 0.06 | 0.08 | 0.06 | |
Net debt to EBITDA | 0.82 | 1.25 | 1.29 | 0.72 | 1.43 | |
Current ratio | 6.52 | 4.78 | 4.94 | 4.99 | 7.98 | |
Interest coverage | 620.38 | 9.45 | 0 | 0 | 0 | |
Income quality | 0.37 | 1.1 | 0.49 | 0.92 | 0.79 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | -0.36 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | -0.64 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.03 | 0.03 | 0.04 | 0.05 | 0.04 | |
Capex to operating cash flow | 0 | 0.01 | 0.01 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.87 | -0.45 | -0.32 | -0.81 | -0.5 | |
Stock based compensation to revenue | -0.54 | 0 | 0 | 0 | 0 | |
Graham number | 25.65 | 12.69 | 13 | 11.97 | 14.77 | |
ROIC | -0.31 | -0.15 | -0.22 | -0.3 | -0.31 | |
Return on tangible assets | -0.31 | -0.12 | -0.19 | -0.28 | -0.29 | |
Graham Net | 6.65 | 4.67 | 3.75 | 2.56 | 3.86 | |
Working capital | 496.95M | 430.47M | 346.27M | 248.39M | 387.02M | |
Tangible asset value | 518.98M | 452.47M | 367.47M | 270.22M | 408.19M | |
Net current asset value | 463.96M | 398.21M | 314.64M | 217.84M | 357.21M | |
Invested capital | 0.13 | 0.06 | 0.08 | 0.11 | 0.07 | |
Average receivables | 28.74M | 44.98M | 26.24M | 10.86M | 13.36M | |
Average payables | 7.72M | 12.58M | 13.25M | 10.78M | 12.55M | |
Average inventory | 37.03M | 72.05M | 78.01M | 51.02M | 16.98M | |
Days sales outstanding | -19.31 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 26.95 | 1.7K | 1.35K | 999.24 | 1.48K | |
Days of inventory on hand | 141.41 | 10.36K | 7.66K | 3.57K | 0 | |
Receivables turnover | -4.66 | 0 | 0 | 0 | 0 | |
Payables turnover | 3.34 | 0.05 | 0.07 | 0.09 | 0.06 | |
Inventory turnover | 0.64 | 0.01 | 0.01 | 0.03 | 0 | |
ROE | -0.37 | -0.15 | -0.23 | -0.35 | -0.34 | |
Capex per share | 0 | -0.01 | -0.01 | -0.02 | -0.01 |
BHVN Frequently Asked Questions
What is Biohaven Pharmaceutical Holding Company Ltd. stock symbol ?
Biohaven Pharmaceutical Holding Company Ltd. is a US stock , located in New haven of Ct and trading under the symbol BHVN
Is Biohaven Pharmaceutical Holding Company Ltd. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $23.5. The lowest prediction is $23 and the highest is $24
What is BHVN stock prediction ?
What is Biohaven Pharmaceutical Holding Company Ltd. stock quote today ?
Biohaven Pharmaceutical Holding Company Ltd. stock price is $54.69 today.
Is Biohaven Pharmaceutical Holding Company Ltd. stock public?
Yes, Biohaven Pharmaceutical Holding Company Ltd. is a publicly traded company.